AlbertoBessudoMD

Oncology • Encinitas, CA

Physician

Join to view full profile

Dr. Bessudo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bessudo's full profile

Already have an account?

Office
326 Santa Fe Dr
Ste 105
Encinitas, CA 92024
Phone+1 760-452-3340

Fax+1 760-452-3344

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1991 - 1992
Aurora Health CareResidency, Internal Medicine, 1989 - 1991
Universidad Nacional Autonoma de MexicoClass of 1989

Certifications & Licensure

CA State Medical License 1991 - 2025
WI State Medical License 1990 - 1991

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
Unknown status
Phase 4
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Feb 01
Unknown status
Phase 1, Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Start of enrollment: 2014 May 01
Completed
Phase 2
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma Start of enrollment: 2014 Mar 01
Unknown status
Phase 2
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule Start of enrollment: 2017 Dec 04
Completed
Phase 1
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Start of enrollment: 2021 Dec 22
Withdrawn
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.
Alberto Bessudo, Abdul Mustajeeb Haseeb, James A Reeves, Xiaofu Zhu, Lucas Wong
Clinical Colorectal Cancer. 2024-09-01
3 citations
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Anthony P Conley, Christina L Roland, Alberto Bessudo, Brian R Gastman, Victoria M Villaflor
Cancer Gene Therapy. 2024-04-01
1 citations
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Jonathan Afari, Tanya M Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo
Experimental Hematology. 2022-10-01

Lectures

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Laekna Therapeutics Reported Positive Results in Two Clinical Studies for the Treatment of Various Stages of Prostate Cancer at the ESMO CongressSeptember 16th, 2021
VerdePharmHealth Signs Exclusive Partnership Agreement with HAI Health for Oncologist-Formulated Medical Cannabis Product LineJune 23rd, 2020